Stock Analiz

Kamada Ltd. KMDA

Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026

$8.09Market cap $467M
Open the interactive analysis →

Kamada Ltd. (KMDA) is a healthcare company listed in the US with a market value of about $467M. In the twelve months to September 30, 2026 it had revenue of $197M and net income of $25M, a net margin of 12.7%.

Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is track record (0/5).

Key numbers: a P/E of 21.3, a price to free cash flow of 13.0, 5-year revenue growth of 6% a year, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 25% below the current price.

About Kamada

Kamada is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $70M in 2015 to $180M in 2025, growth of about 9.9% a year. It was profitable in 7 of the last 10 years in our data.

Score: 2.8 / 5

Value3/5
Future growth3/5
Track record0/5
Financial health5/5
Shareholder returns3/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)21.3
Forward P/E15.6
P/FCF13.0
P/S2.4
P/B1.7
EV/EBITDA9.1
PEG—
Dividend yield2.11%
FCF yield7.7%
Shareholder yield2.1%
Intrinsic value vs. price−25%

Growth and quality

Revenue growth (1 yr)12.1%
Revenue growth (5 yrs, per year)6.2%
EPS growth (5 yrs, per year)-1.6%
FCF growth (3 yrs, per year)-14.2%
Net margin (5-yr avg.)4.4%
ROIC (5-yr avg.)4.0%
Profitable years (of last 10)7
Years paying a dividend1

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$197M$180M$161M$143M$129M$104M$133M$127M$114M$103M$77M
Net income$25M$20M$14M$8M-$2M-$2M$17M$22M$22M$7M-$7M
Free cash flow$36M$16M$37M-$2M$25M-$13M$14M$25M$8M-$559000-$744000
EPS (diluted)$0.43$0.35$0.25$0.14$-0.04$-0.04$0.30$0.39$0.39$0.12$-0.12
Net margin12.7%11.2%9.0%5.8%-1.8%-2.1%12.9%17.5%19.5%6.7%-8.7%
ROIC—8.4%6.1%4.0%1.8%-0.3%9.9%16.2%13.4%7.8%-6.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $13.75, 70% above the current price; targets range from $12.00 to $15.00; the consensus rating is “Strong buy”; expected EPS is $0.47 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Kamada’s P/E ratio?

About 21.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.6).

Is Kamada stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 25% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Kamada pay a dividend?

Yes. The dividend yield is about 2.11%, and it has paid dividends for 1 years in our data.

Is Kamada a good stock to buy?

We do not give buy or sell advice. Kamada scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.